{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:40:59Z","timestamp":1789756859898,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-0872-5","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T20:32:37Z","timestamp":1427488357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"15","author":[{"given":"Li-Chao","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Wen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Fu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"issue":"6","key":"872_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","volume":"188","author":"PJ McShane","year":"2013","unstructured":"McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647\u201356.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"872_CR2","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"MC Pasteur","year":"2010","unstructured":"Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non CFGG. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65 Suppl 1:i1\u201358.","journal-title":"Thorax"},{"issue":"2","key":"872_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1378\/chest.11-2209","volume":"142","author":"AE Seitz","year":"2012","unstructured":"Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142(2):432\u20139.","journal-title":"Chest"},{"issue":"8","key":"872_CR4","doi-asserted-by":"publisher","first-page":"e71109","DOI":"10.1371\/journal.pone.0071109","volume":"8","author":"FC Ringshausen","year":"2013","unstructured":"Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in Germany, 2005\u20132011: a population-based study of disease burden and trends. PLoS One. 2013;8(8):e71109.","journal-title":"PLoS One"},{"key":"872_CR5","first-page":"6","volume":"147","author":"PJ Cole","year":"1986","unstructured":"Cole PJ. Inflammation: a two-edged sword\u2013the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6\u201315.","journal-title":"Eur J Respir Dis Suppl"},{"key":"872_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.rppneu.2013.03.006","volume":"19","author":"A Amorim","year":"2013","unstructured":"Amorim A, Gamboa F, Azevedo P. New advances in the therapy of non-cystic fibrosis bronchiectasis. Rev Port Pneumol. 2013;19:266\u201375.","journal-title":"Rev Port Pneumol"},{"issue":"4","key":"872_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10787-012-0165-1","volume":"21","author":"PM Bartold","year":"2013","unstructured":"Bartold PM, du Bois AH, Gannon S, Haynes DR, Hirsch RS. Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis. Inflammopharmacology. 2013;21(4):321\u201338.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"872_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1124\/jpet.112.200733","volume":"345","author":"Y Kobayashi","year":"2013","unstructured":"Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther. 2013;345(1):76\u201384.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"872_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/CMR.00078-09","volume":"23","author":"S Kanoh","year":"2010","unstructured":"Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590\u2013615.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"872_CR10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1183\/09031936.99.13613809","volume":"13","author":"H Nakamura","year":"1999","unstructured":"Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999;13(6):1371\u20139.","journal-title":"Eur Respir J"},{"issue":"10","key":"872_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/thx.52.10.915","volume":"52","author":"H Koyama","year":"1997","unstructured":"Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax. 1997;52(10):915\u20138.","journal-title":"Thorax"},{"issue":"11","key":"872_CR12","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.rmed.2008.03.009","volume":"102","author":"G Steinkamp","year":"2008","unstructured":"Steinkamp G, Schmitt-Grohe S, Doring G, Staab D, Pfrunder D, Beck G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med. 2008;102(11):1643\u201353.","journal-title":"Respir Med"},{"issue":"8","key":"872_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689\u201398.","journal-title":"N Engl J Med"},{"issue":"10","key":"872_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thx.2005.057950","volume":"61","author":"A Clement","year":"2006","unstructured":"Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006;61(10):895\u2013902.","journal-title":"Thorax"},{"issue":"1","key":"872_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","volume":"172","author":"JP Higgins","year":"2009","unstructured":"Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137\u201359.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"12","key":"872_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.2013.2290","volume":"309","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260\u20137.","journal-title":"JAMA"},{"issue":"9842","key":"872_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660\u20137.","journal-title":"Lancet"},{"issue":"12","key":"872_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251\u20139.","journal-title":"JAMA"},{"issue":"7","key":"872_CR19","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/resp.12130","volume":"18","author":"AD Diego","year":"2013","unstructured":"Diego AD, Milara J, Martinez-Moragon E, Palop M, Leon M, Cortijo J. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology. 2013;18(7):1056\u201362.","journal-title":"Respirology"},{"issue":"5","key":"872_CR20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1183\/09031936.97.10050994","volume":"10","author":"YY Koh","year":"1997","unstructured":"Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J. 1997;10(5):994\u20139.","journal-title":"Eur Respir J"},{"issue":"2","key":"872_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1183\/09031936.99.13236199","volume":"13","author":"KW Tsang","year":"1999","unstructured":"Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J. 1999;13(2):361\u20134.","journal-title":"Eur Respir J"},{"issue":"1","key":"872_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2710.2006.00708.x","volume":"31","author":"E Yalcin","year":"2006","unstructured":"Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther. 2006;31(1):49\u201355.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"872_CR23","first-page":"824","volume":"35","author":"JF Liu","year":"2012","unstructured":"Liu JF, Zhong XN, He ZY, Zhong DJ, Bai J, Zhang JQ, et al. Impact of treatment with low dose roxithromycin on stable bronchiectasis. Chinese J TB Res Dis. 2012;35(11):824\u20137.","journal-title":"Chinese J TB Res Dis"},{"issue":"2","key":"872_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00151829-200504020-00005","volume":"4","author":"AA Cymbala","year":"2005","unstructured":"Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4(2):117\u201322.","journal-title":"Treat Respir Med"},{"issue":"8","key":"872_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2213-2600(13)70185-1","volume":"1","author":"PC Valery","year":"2013","unstructured":"Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Res Med. 2013;1(8):610\u201320.","journal-title":"Lancet Res Med"},{"issue":"8","key":"872_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/qjmed\/hct109","volume":"106","author":"MJ McDonnell","year":"2013","unstructured":"McDonnell MJ, Ward C, Lordan JL, Rutherford RM. Non-cystic fibrosis bronchiectasis. QJM. 2013;106(8):709\u201315.","journal-title":"QJM"},{"issue":"3","key":"872_CR27","doi-asserted-by":"publisher","first-page":"e90047","DOI":"10.1371\/journal.pone.0090047","volume":"9","author":"YH Gao","year":"2014","unstructured":"Gao YH, Guan WJ, Xu G, Tang Y, Gao Y, Lin ZY, et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90047.","journal-title":"PLoS One"},{"issue":"3","key":"872_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.pupt.2012.12.006","volume":"26","author":"ZL Shi","year":"2013","unstructured":"Shi ZL, Peng H, Hu XW, Hu JG. Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review. Pulm Pharmacol Ther. 2013;26(3):307\u201317.","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"872_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.pupt.2013.12.006","volume":"28","author":"DJ Serisier","year":"2014","unstructured":"Serisier DJ. Letter to the editor: inaccurate data in meta-analysis of macrolides by Shi et al. Pulm Pharmacol Ther. 2014;28(2):179.","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"872_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.pupt.2013.12.004","volume":"27","author":"YH Gao","year":"2014","unstructured":"Gao YH, Guan WJ, Xu G, Chen RC. Macrolide treatment in patients with bronchiectasis: more attention should be paid to the number of exacerbations. Pulm Pharmacol Ther. 2014;27(2):213\u20134.","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"872_CR31","first-page":"540","volume":"59","author":"G Davies","year":"2004","unstructured":"Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax. 2004;59(6):540\u20131.","journal-title":"Thorax"},{"issue":"6","key":"872_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.rmed.2011.01.009","volume":"105","author":"DJ Serisier","year":"2011","unstructured":"Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med. 2011;105(6):946\u20139.","journal-title":"Respir Med"},{"issue":"10","key":"872_CR33","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.rmed.2008.06.005","volume":"102","author":"GA Anwar","year":"2008","unstructured":"Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med. 2008;102(10):1494\u20136.","journal-title":"Respir Med"},{"issue":"1","key":"872_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1164\/ajrccm\/141.1.72","volume":"141","author":"SK Goswami","year":"1990","unstructured":"Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis. 1990;141(1):72\u20138.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"872_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/AAC.02067-13","volume":"58","author":"H Li","year":"2014","unstructured":"Li H, Liu DH, Chen LL, Zhao Q, Yu YZ, Ding JJ, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother. 2014;58(1):511\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"872_CR36","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881\u201390.","journal-title":"N Engl J Med"},{"issue":"3","key":"872_CR37","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","volume":"1","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Res Med. 2013;1(3):262\u201374.","journal-title":"Lancet Res Med"},{"issue":"3","key":"872_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/resp.12247","volume":"19","author":"DJ Serisier","year":"2014","unstructured":"Serisier DJ. The evidence base for non-CF bronchiectasis is finally evolving. Respirology. 2014;19(3):295\u20137.","journal-title":"Respirology"},{"issue":"3","key":"872_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/resp.12233","volume":"19","author":"Q Wu","year":"2014","unstructured":"Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology. 2014;19(3):321\u20139.","journal-title":"Respirology"},{"issue":"2","key":"872_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jac\/45.2.191","volume":"45","author":"D Felmingham","year":"2000","unstructured":"Felmingham D, Gruneberg RN. The Alexander Project 1996\u20131997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45(2):191\u2013203.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"872_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jac\/dkg321","volume":"52","author":"MR Jacobs","year":"2003","unstructured":"Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, Alexander Project G. The Alexander Project 1998\u20132000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52(2):229\u201346.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"872_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1128\/JCM.40.1.159-164.2002","volume":"40","author":"C Garcia-Rey","year":"2002","unstructured":"Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol. 2002;40(1):159\u201364.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"872_CR43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1017\/S0950268807009405","volume":"136","author":"R Dias","year":"2008","unstructured":"Dias R, Canica M. Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal. Epidemiol Infect. 2008;136(7):928\u201339.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"872_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1086\/341078","volume":"186","author":"MA Leverstein-van Hall","year":"2002","unstructured":"Leverstein-van Hall MA, Box AT, Blok HE, Paauw A, Fluit AC, Verhoef J. Evidence of extensive interspecies transfer of integron-mediated antimicrobial resistance genes among multidrug-resistant Enterobacteriaceae in a clinical setting. J Infect Dis. 2002;186(1):49\u201356.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-0872-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0872-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0872-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0872-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T02:01:11Z","timestamp":1717812071000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-0872-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-0872-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]},"assertion":[{"value":"14 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"160"}}